疟疾是全球危害最严重的蚊媒传染病之一。随着疟原虫抗药性由单一性向多药抗性发展，在与我国西南边陲毗邻的大湄公河次区域出现青蒿素耐药性虫株，这使我国境外输入疟疾病例显著升高。疟疾防治迫切需要加快新型抗疟药物研发。抗菌肽广泛分布于动植物体内，因高效、广谱且不易导致微生物耐药而成为新型抗感染药物研究的热点。我们近期的研究发现金环蛇毒素来源抗菌肽cathelicidin-BF衍生多肽LZ1具有明显的抗疟原虫活性，以cathelicidin-BF为骨架设计合成并筛选出一批优秀的衍生多肽。本研究将在前期研究的基础上，深入研究该系列衍生多肽的抗疟原虫的活性及作用机制。主要包括1）衍生多肽的药物化学特性研究；2）衍生多肽的体外抗疟原虫作用及机制研究（细胞水平）；3）衍生多肽的体内抑制疟原虫感染的作用及机制研究（动物水平）。该研究将阐明多肽类新型抗疟药物的作用机制，同时提供潜在的抗疟原虫药物候选分子。

Malaria is transmitted by mosquito vectors and is one of the most serious infectious diseases in the world. With the development of malaria parasite resistance from singleness to multidrug resistance, and the emergence of artemisinin-resistant Plasmodium falciparum strains in the Greater Mekong subregion adjacent to the southwestern border of China, this has significantly increased the number of imported malaria cases into our country. To control malaria, there is an urgent need to accelerate the pace of new antimalarials development. Antimicrobial peptides are widely distributed in plants and animals. They have become the focus of research on new anti-infective drugs, because of their high efficiency, broad spectrum and little drug-resistant. In our recent research, an antimicrobial peptides LZ1 derived from snake cathelicidin was identified with antimalarial activity. Based on Cathelicidin-BF a series of small peptides were designed and synthesized. In the future study, we will further take research on the mechanism of this series of derived antimalarial peptides. It mainly includes 1) study on the medicinal and chemical properties of the cathelicidin-BF-derived antimicrobial peptide; 2) study on the in vitro antimalarial activity and mechanism of the derived peptide (cell level); 3) study on the in vivo antimalarial activity and mechanism of the derived peptide (animal level). We are looking forward to elucidate the antimalarial mechanism of cathelicidin-BF-derived antimicrobial peptide, and provide potential antimalarial drug candidates.